Standard BioTools Inc.
LAB Healthcare Medical Devices
In the quarter to June 2026, revenue fell 7.62%, EPS grew 22.2%, free cash flow grew 52.8% and total debt was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow LAB
Standard BioTools Inc. (LAB) Piotroski F-score
Standard BioTools Inc.'s Piotroski F-score for fiscal 2025 is 4 out of 9: 4 of nine tests of profitability, leverage and efficiency passed, unchanged from fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 4 | 0.00 |
| FY2024 | 4 | (1.00) |
| FY2023 | 5 | 2.00 |
| FY2022 | 3 | 2.00 |
| FY2021 | 1 | (4.00) |
| FY2020 | 5 | 1.00 |
| FY2019 | 4 | (2.00) |
| FY2018 | 6 | 3.00 |
| FY2017 | 3 | 1.00 |
| FY2016 | 2 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (12.69%) | (39.53%) | Fail | 0 |
| Positive operating cash flow | (74.34m) | (143.45m) | Fail | 0 |
| Rising return on assets | (12.69%) | (39.53%) | Pass | 1 |
| Cash flow above net income | 553.00k | 41.45m | Pass | 1 |
| Falling long-term leverage | 0.00 | 0.00 | Pass | 1 |
| Rising current ratio | 4.19 | 5.70 | Fail | 0 |
| No new shares issued | 381,623,000 | 353,245,000 | Fail | 0 |
| Rising gross margin | 49.86% | 49.32% | Pass | 1 |
| Rising asset turnover | 0.14 | 0.19 | Fail | 0 |
| Piotroski F-score | Mixed | 4 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| INFU InfuSystems Holdings, Inc. compare | 8 |
| ELMD Electromed, Inc. compare | 8 |
| CLPT ClearPoint Neuro, Inc. compare | 4 |
| LAB Standard BioTools Inc. | 4 |
| CATX Perspective Therapeutics, Inc. compare | 3 |
| TLSI TriSalus Life Sciences, Inc. compare | 3 |
| TMCI Treace Medical Concepts, Inc. compare | 2 |
| QSI Quantum-Si Incorporated compare | 2 |
| PROF Profound Medical compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover